CREDIT CARDS ACCEPTED | 6% OFF CRYPTO | 3RD-PARTY TESTING (JANOSHIK)
Menu
Cart
CJC-1295 + Ipamorelin Blend 5mg / 5mg - 10 Vial Box
cjc-1295 no-dac janoshik test
ipamorelin janoshik third-party test
CJC-1295 no-DAC certificate of analysis
CJC-1295 no-DAC hplc
Ipamorelin certificate of analysis
Ipamorelin hplc

CJC-1295 + Ipamorelin Blend 5mg / 5mg – 10 Vial Box

$410.00

Cost per vial $: 41

Buy CJC-1295 (no DAC) + ipamorelin blend 5 mg (one 10-vial box). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
Quantity Bulk Discount Price
2 5% $389.50
3-5 7% $381.30
6-10 10% $369.00
SKU: CJCIPA5 Categories: ,

Description

CJC-1295 without DAC is a synthetic peptide that increases the release of growth hormone by stimulating the pituitary gland by mimicking the effects of growth hormone–releasing hormone (GHRH). Ipamorelin is another peptide that tells the body to produce and release more growth hormone by mimicking the action of the natural peptide ghrelin.

CJC-1295 has shown synergistic effects on growth hormone when combined with ipamorelin because they work through different, complementary mechanisms.

Minimum order quantity: one box (10 vials x 5/5 mg)

Additional information

Purity

≥99.0%
Cost per vial $

41
  1. Raun, Kirsten, et al. "Ipamorelin, the first selective growth hormone secretagogue." European journal of endocrinology 139.5 (1998): 552-561.
  2. Andersen, N. B., et al. "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats." Growth Hormone & IGF Research 11.5 (2001): 266-272.
  3. Beck, David E., et al. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International journal of colorectal disease 29 (2014): 1527-1534.
  4. Gobburu, Jogarao VS, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical research 16 (1999): 1412-1416.
  5. Schally, Andrew V., et al. "Actions and potential therapeutic applications of growth hormone–releasing hormone agonists." Endocrinology 160.7 (2019): 1600-1612.
  6. Valcavi, R., et al. "Growth hormone responses to GRF 1–29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine." Clinical endocrinology 24.6 (1986): 693-698.
  7. Ionescu, Madalina, and Lawrence A. Frohman. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." The Journal of Clinical Endocrinology & Metabolism 91.12 (2006): 4792-4797.
  8. Teichman, Sam L., et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." The Journal of Clinical Endocrinology & Metabolism 91.3 (2006): 799-805.

Ipamorelin CoA 2024

Ipamorelin HPLC

CJC-1295 NO DAC COA 2024

CJC-1295 NO DAC HPLC

Related products